Inflammation & Infection

Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects

July 10, 2022

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

Cost of treatment discourages adherence for patients with dry eye disease associated with Sjögren’s syndrome

May 28, 2022

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.